Please ensure Javascript is enabled for purposes of website accessibility

Why Mednax Is Crashing 21.2% Today

By Todd Campbell – Feb 20, 2020 at 12:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The specialized health services provider's fourth-quarter financials were uninspiring.

What happened

Shares of Mednax (MD -2.19%) were tumbling 21.2% at 12 p.m. EST Thursday after management reported fourth-quarter earnings per share (EPS) that fell shy of industry watchers' expectations and that the nation's largest insurer, UnitedHealth Group (UNH -1.51%) is cancelling contracts with its physician groups. 

So what

Mednax is one of the biggest providers of neonatal and anesthesia services to medical facilities. Its revenue has climbed thanks to acquisitions of smaller provider groups. Unfortunately, higher costs associated with paying its specialists have created headwinds to its profit growth.

A man holds his head in his hands while looking at a declining stock price chart.

Image source: Getty Images.

In Q4 2019, revenue inched up 1.9% year over year to $905.4 million. That was $4.5 million better than analysts wanted, but its EPS under generally accepted accounting principles (GAAP) of $0.40 missed the mark by $0.09. For the full year, revenue increased to $3.51 billion from $3.45 billion in 2018, but adjusted EPS from continuing operations fell to $3.38 from $3.55 in 2018.

The news that UnitedHealth Group has cancelled contracts with Mednax in four states for all its services increases concern that the company's earnings will face greater pressure this year. The contracts had effective dates ranging from March 1 to Sept. 1, 2020 and accounted for about 2% of Mednax's annual revenue last year. Mednax expressed hope that it can come to terms with UnitedHealth, but pushback against out-of-network bills for patients may put insurers in the driver's seat in negotiations.

Now what

A larger, longer-living population provides tailwinds to long-term demand for this healthcare company's services, but expense control could remain a problem. Practice salaries and benefits increased to 71.4% of revenue in 2019 from 70.2% in 2018 and uncertainty associated with UnitedHealth's decision led to management acknowledging it's "not able to forecast the outcome of this matter, nor estimate the potential impact to its results."

Given the headwinds, investors should probably focus on other stocks until there's more clarity, rather than trying to buy Mednax on sale.

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MEDNAX Stock Quote
MEDNAX
MD
$16.93 (-2.19%) $0.38
UnitedHealth Group Incorporated Stock Quote
UnitedHealth Group Incorporated
UNH
$519.13 (-1.51%) $-7.94

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.